Overall verdict
Buy
6.5/10
1-year performance
+159.96%
Score breakdown
Up 160.0% over 1 year, 96% of the 52-week range.
Strongest: Growth 10.0/10. Weakest: Valuation 2.7/10.
17 analysts, target +0.1% vs the price.
Hinge Health, Inc. focuses on building a health system that scales and automates the delivery of care using technology. It designs its platform to address musculoskeletal system care (MSK), including acute injury, chronic pain, and post-surgical rehabilitation. The company also provides personalized and automated MSK care through AI-powered motion tracking technology and a proprietary electrical nerve stimulation wearable device. It primarily serves self-insured employers. The company was founded in 2012 and is headquartered in San Francisco, California.
Sector
Health Care
Industry
Health Care Providers and Services
Primary listing
Nyse
United States
CEO
Daniel Perez
Founded
2012
Employees
143
Revenue / employee
4.1M USD
Next earnings
February 10, 2027 (estimated)
Institutional holders
- GEODE CAPITAL MANAGEMENT, LLC1.60%
- FMR LLC0.47%
- Bank of New York Mellon Corp0.17%
- Rest of the register97.75%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
124.94 USD
52-week low
30.08 USD
1-year performance
159.96%
Rising
Year-to-date performance
160.85%
Rising
Drawdown
-3.04%
Near its high
Position in the 52-week range
96% of range
Range: 46.81 USD - 53.62 USD (comparables only)
Gross margin 85.7%, net margin 20.7%, ROIC 44.7%, ROE 46.8%.
Net margin
20.68%
Exceptional
Sector 4.51%|S&P 13.40%
Gross margin
85.73%
Exceptional
Return on equity (ROE)
46.83%
Exceptional
Sector 10.36%|S&P 17.06%
Return on invested capital (ROIC)
44.68%
Exceptional
Free cash flow margin (FCF)
39.37%
Exceptional
Profit-to-cash conversion (FCF conversion)
1.90x
High
Revenue to net income
Growth
10.0/10Revenue up 52.4% over 1 year.
Revenue (trailing 12 months)
801M USD
Revenue growth (1y)
52.37%
Hyper-growth
Revenue growth (3y)
—
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
5.81%
Sharply revised up
Valuation
2.7/10P/E 61.0x, forward P/E 52.9x, EV/EBITDA 58.9x, PEG 0.02.
P/E (TTM)
61.0x
Very expensive
Sector 27.0x|S&P 23.6x
Forward P/E
52.9x
Very expensive
EV / EBITDA
58.9x
Very expensive
Sector 12.5x|S&P 15.5x
PEG
0.02
Growth unpriced
Sector 0.78|S&P 0.91
Fair value (reverse DCF)
50.21 USD
Deeply overvalued
Market cap
9.4Md USD
Financial strength
10.0/10Cash covers 869.8% of the debt, no net debt (net cash).
Net debt / EBITDA
—
Gearing (net debt / equity)
-87.09%
Net cash
Cash
295M USD
Cash / market cap
3.12%
Tight
Cash / total debt
869.75%
Net cash
Net debt
-261M USD
Equity
299M USD
Closed daily candles, 18 months
Last close on November 10, 2026: 123.23 USD
- MM20112.83
- MM50102.14
- MM20069.73
- RSI 1470.7
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+11.19%
200-day average slope, 3 months
+31.24%
50-day average slope, 1 month
+11.58%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
2.73 % per day
Volatility change
-3.56%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 2.29 (10) | 2.57 (14) | 878 (16) | 270 (10) | 185 (10) |
| 2027 | 2.97 (9) | 3.26 (14) | 1 115 (16) | 354 (10) | 225 (9) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 10, 2026.
Same sub-industry: 76 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | DVA | 6.6 | 6.5 | 11.5Md USD | 13.9x | 6.3 % | 4.6 % | 7.5 % | 4.5x | 11.2 % | 52.1 % | ||
| 2 | CVS | 6.5 | 6.0 | 115Md USD | 10.4x | 2.6 % | 5.4 % | 7.4 % | 4.1x | 13.6 % | 14.8 % | ||
| 3 | HNGE | 6.5 | 7.0 | 9.4Md USD | 61.0x | 20.7 % | 52.4 % | 44.7 % | — | 3.3 % | 160.0 % | ||
| 4 | DGX | 6.1 | 6.1 | 28.5Md USD | 25.8x | 9.5 % | 10.0 % | 8.4 % | 2.8x | 4.8 % | 39.8 % | ||
| 5 | CI | 6.1 | 6.1 | 79.4Md USD | 13.3x | 2.1 % | 5.7 % | 8.3 % | 1.8x | 10.4 % | 15.8 % | ||
| 6 | BTSG | 6.0 | 4.7 | 14.5Md USD | 47.2x | 2.0 % | 26.4 % | 7.0 % | 4.6x | 3.4 % | 116.3 % | ||
| 7 | FME | 5.4 | 5.4 | 12.0Md USD | 13.6x | 4.2 % | 1.1 % | 3.8 % | 2.7x | 17.0 % | -0.5 % | ||
| 8 | GH | 5.3 | 3.6 | 20.9Md USD | Not meaningful (loss) | -37.9 % | 36.1 % | -41.6 % | -1.4x | -1.1 % | 59.9 % | ||
| 9 | LH | 5.3 | 4.4 | 30.2Md USD | 30.5x | 6.9 % | 6.9 % | 6.8 % | 2.4x | 4.3 % | 41.7 % |
